Market Overview

Why Cormedix's Stock Is Trading Higher Today

Share:
Why Cormedix's Stock Is Trading Higher Today

Cormedix (NYSE: CRMD) shares are trading higher on Monday after Truist Securities initiated coverage on the stock with a Buy rating and a price target of $20 per share.

Cormedix is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution or the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology.

Cormedix shares were trading up 6.7% at $4.92 at the time of publication. The stock has a 52-week high of $8.64 and a 52-week low of $2.16.

Latest Ratings for CRMD

DateFirmActionFromTo
Sep 2020JMP SecuritiesInitiates Coverage OnMarket Outperform
Sep 2020Truist SecuritiesInitiates Coverage OnBuy
Aug 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for CRMD
View the Latest Analyst Ratings

 

Related Articles (CRMD)

View Comments and Join the Discussion!

Posted-In: why it's movingPenny Stocks Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com